SHANGHAI, May 26 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that management will attend Digestive Disease Week 2009 ("DDW 2009").
Digestive Disease Week (DDW) is the largest and most prestigious meeting in the world for gastrointestinal professionals in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Every year, it attracts approximately 16,000 physicians, researchers and academics from around the world. The schedule for DDW 2009 is:
May 30 - June 4, 2009 Exhibit Dates: May 31 - June 3, 2009 McCormick Place Chicago, IL
"We are excited to attend this important industry event, which we believe will enhance our profile with scientists and medical professionals in North America," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "We look forward to leveraging this tremendous platform to enhance our visibility in the international community."
About China-Biotics, Inc.
China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact: CCG Investor Relations Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: email@example.com Web: http://www.ccgirasia.com
|SOURCE China-Biotics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved